Cargando…

The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics

Traditionally, bacteriostatic antibiotics are agents able to arrest bacterial growth. Despite being unable to kill bacterial cells, when they are used clinically the outcome of these drugs is frequently as effective as when a bactericidal drug is used. We explore the dynamics of Escherichia coli aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Gil-Gil, Teresa, Berryhill, Brandon A., Manuel, Joshua A., Smith, Andrew P., McCall, Ingrid C., Baquero, Fernando, Levin, Bruce R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634941/
https://www.ncbi.nlm.nih.gov/pubmed/37961139
http://dx.doi.org/10.1101/2023.10.30.564761
_version_ 1785146264913969152
author Gil-Gil, Teresa
Berryhill, Brandon A.
Manuel, Joshua A.
Smith, Andrew P.
McCall, Ingrid C.
Baquero, Fernando
Levin, Bruce R.
author_facet Gil-Gil, Teresa
Berryhill, Brandon A.
Manuel, Joshua A.
Smith, Andrew P.
McCall, Ingrid C.
Baquero, Fernando
Levin, Bruce R.
author_sort Gil-Gil, Teresa
collection PubMed
description Traditionally, bacteriostatic antibiotics are agents able to arrest bacterial growth. Despite being unable to kill bacterial cells, when they are used clinically the outcome of these drugs is frequently as effective as when a bactericidal drug is used. We explore the dynamics of Escherichia coli after exposure to two ribosome-targeting bacteriostatic antibiotics, chloramphenicol and azithromycin, for thirty days. The results of our experiments provide evidence that bacteria exposed to these drugs replicate, evolve, and generate a sub-population of small colony variants (SCVs) which are resistant to multiple drugs. These SCVs contribute to the evolution of heteroresistance and rapidly revert to a susceptible state once the antibiotic is removed. Stated another way, exposure to bacteriostatic drugs selects for the evolution of heteroresistance in populations previously lacking this trait. More generally, our results question the definition of bacteriostasis as populations exposed to bacteriostatic drugs are replicating despite the lack of net growth.
format Online
Article
Text
id pubmed-10634941
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-106349412023-11-13 The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics Gil-Gil, Teresa Berryhill, Brandon A. Manuel, Joshua A. Smith, Andrew P. McCall, Ingrid C. Baquero, Fernando Levin, Bruce R. bioRxiv Article Traditionally, bacteriostatic antibiotics are agents able to arrest bacterial growth. Despite being unable to kill bacterial cells, when they are used clinically the outcome of these drugs is frequently as effective as when a bactericidal drug is used. We explore the dynamics of Escherichia coli after exposure to two ribosome-targeting bacteriostatic antibiotics, chloramphenicol and azithromycin, for thirty days. The results of our experiments provide evidence that bacteria exposed to these drugs replicate, evolve, and generate a sub-population of small colony variants (SCVs) which are resistant to multiple drugs. These SCVs contribute to the evolution of heteroresistance and rapidly revert to a susceptible state once the antibiotic is removed. Stated another way, exposure to bacteriostatic drugs selects for the evolution of heteroresistance in populations previously lacking this trait. More generally, our results question the definition of bacteriostasis as populations exposed to bacteriostatic drugs are replicating despite the lack of net growth. Cold Spring Harbor Laboratory 2023-10-30 /pmc/articles/PMC10634941/ /pubmed/37961139 http://dx.doi.org/10.1101/2023.10.30.564761 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Gil-Gil, Teresa
Berryhill, Brandon A.
Manuel, Joshua A.
Smith, Andrew P.
McCall, Ingrid C.
Baquero, Fernando
Levin, Bruce R.
The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics
title The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics
title_full The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics
title_fullStr The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics
title_full_unstemmed The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics
title_short The Evolution of Heteroresistance via Small Colony Variants in Escherichia coli Following Long Term Exposure to Bacteriostatic Antibiotics
title_sort evolution of heteroresistance via small colony variants in escherichia coli following long term exposure to bacteriostatic antibiotics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634941/
https://www.ncbi.nlm.nih.gov/pubmed/37961139
http://dx.doi.org/10.1101/2023.10.30.564761
work_keys_str_mv AT gilgilteresa theevolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics
AT berryhillbrandona theevolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics
AT manueljoshuaa theevolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics
AT smithandrewp theevolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics
AT mccallingridc theevolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics
AT baquerofernando theevolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics
AT levinbrucer theevolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics
AT gilgilteresa evolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics
AT berryhillbrandona evolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics
AT manueljoshuaa evolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics
AT smithandrewp evolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics
AT mccallingridc evolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics
AT baquerofernando evolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics
AT levinbrucer evolutionofheteroresistanceviasmallcolonyvariantsinescherichiacolifollowinglongtermexposuretobacteriostaticantibiotics